NCJ Number
173651
Journal
Loy. L.A. International and Comparative Law Journal Volume: 18 (1996) Issue: Dated: Pages: 841-864
Date Published
1996
Length
24 pages
Annotation
This paper analyzes the problems that the United States will experience in attempting to stop the smuggling of the drug Rohypnol after the passage of the North American Free Trade Agreement (NAFTA).
Abstract
This drug is a benzodiazepine pharmaceutical produced in pill form in several countries and used for severe insomnia, psychosis, or sedation of persons preparing to undergo surgery. The use of this drug is increasing sharply, particularly in States along the Mexican border where it is readily available. Rohypnol is currently listed as a schedule IV drug, as are most sleeping aids. Most States have made Rohypnol possession a State crime. Border interception of Rohypnol is currently very difficult and will become more difficult as a result of NAFTA. In addition, increased penalties are unlikely to prevent the influx of Rohypnol, given that crack cocaine abuse has not decreased in proportion to the increase in penalty. Therefore, the United States needs to take a proactive approach to prevent the drug smuggling before it begins. The focus should be on both stopping the drugs at their source and expanding drug prevention programs to reduce the demand that makes smuggling profitable. Footnotes